文献速递前列腺癌

现有种系BRCA1/2突变风险预测工具在前列腺癌患者中表现不佳

Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
PubMed 文献 · Eur Urol Oncol · 2019-07-13

本研究分析了106个已知BRCA1/BRCA2突变的家族(其中23个含前列腺癌病例),评估BRCAPRO与曼彻斯特评分系统(MSS)能否识别出应接受检测的前列腺癌患者。结果仅30%(BRCAPRO)和48%(MSS)的已知BRCA1/BRCA2突变携带者前列腺癌患者符合检测条件,提示这两种工具在前列腺癌人群中表现不佳。

要点

  • 在已知BRCA1/BRCA2突变携带者的前列腺癌患者中,仅30%符合BRCAPRO检测条件,48%符合MSS检测条件。
  • 从首个携带者前列腺癌病例到导致种系检测的癌症病例之间,每个家族中位发生2例乳腺癌和/或卵巢癌。
  • 作者认为这些工具在前列腺癌患者中表现不佳,不应在此人群中用于优化检测。

核心结论

  • BRCAPRO和MSS在已知BRCA1/BRCA2突变携带者的前列腺癌患者中表现不佳,不应在前列腺癌人群中用于优化检测。

研究设计与样本

  • 分析106个已知BRCA1/BRCA2突变的家族,其中23个家族含前列腺癌病例,评估BRCAPRO与曼彻斯特评分系统(MSS)两种风险计算模型。

主要发现

  • 在已知BRCA1/BRCA2突变携带者的前列腺癌患者中,仅30%符合BRCAPRO检测条件,48%符合MSS检测条件。
  • 从家族中首个被识别的前列腺癌携带者病例到导致种系检测的癌症病例之间,每个家族中位发生2例乳腺癌和/或卵巢癌。

临床怎么用

  • 作者认为BRCAPRO和MSS不应在前列腺癌患者中用于优化BRCA1/2检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early identification of germline BRCA1/2 mutations may be relevant for the management of patients with prostate cancer (PC) and to prevent future breast and ovarian cancers in their relatives. Several prediction tools have been developed to estimate the likelihood of a germline BRCA1/2 mutation and are widely used to optimize screening in breast and ovarian cancer patients. We aimed to elucidate the proportion of PC patients with known BRCA1/2 mutations who would have qualified for testing using two risk calculation models (BRCAPRO and the Manchester scoring system [MSS]). We analyzed 106 families with known BRCA1/BRCA2 mutations, including 23 with PC cases. Only 30% and 48% of PC patients who were known BRCA1/BRCA2 mutations carriers would have qualified for testing using BRCAPRO and MSS, respectively. A median of two breast and/or ovarian cancer cases per family had occurred between the first PC identified in a carrier and the cancer case leading to germline testing. PATIENT SUMMARY: We tested two models developed to predict the probability of inherited BRCA1/BRCA2 mutations and found that these tools underperform in men with prostate cancer and should not be used to optimize testing in this population.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Oliva L, Lozano R, Llácer C, et al. Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients. Eur Urol Oncol. 2019. PMID: 31307957. doi:10.1016/j.euo.2019.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。